Last edition
News about "Trastuzumab Deruxtecan"
AstraZeneca India to Launch Hyperkalaemia Treatment Lokelma in November 2025
AstraZeneca Pharma India Limited (AZPIL) has announced the upcoming launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in India in November 2025.
Trastuzumab Deruxtecan | 15/10/2025 | By Dineshwori | 559
Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer
Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />
Trastuzumab Deruxtecan | 08/10/2025 | By Dineshwori | 449
CDSCO approves AstraZeneca's Trastuzumab Deruxtecan for More HER2-Positive Tumours
With this, Trastuzumab Deruxtecan becomes India’s first Antibody Drug Conjugate (ADC) approved for a tumour-agnostic indication.
Trastuzumab Deruxtecan | 04/10/2025 | By Dineshwori | 233
US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer
The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.
Trastuzumab Deruxtecan | 25/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy